Pituitary Apoplexy Following Chlorpromazine Stimulation

Victor E. Silverman, A. E. Boyd, John A. Mccrary, Peter Kohler

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chlorpromazine is frequently administered to patients with hyperprolactinemia to stimulate an increase in the serum levels of prolactin. A patient with a prolactin secreting adenoma is described in whom pituitary apoplexy developed in association with a hypotensive episode following the administration of 25 mg of chlorpromazine. Prolactin levels fell from more than 2,000 ng/ml to 340 ng/ml following infarction of the pituitary tumor. Pituitary apoplexy should be considered as a rare complication of chlorpromazine stimulation in a patient with a pituitary tumor.

Original languageEnglish (US)
Pages (from-to)1738-1739
Number of pages2
JournalArchives of Internal Medicine
Volume138
Issue number11
DOIs
StatePublished - 1978
Externally publishedYes

Fingerprint

Pituitary Apoplexy
Chlorpromazine
Prolactin
Pituitary Neoplasms
Hyperprolactinemia
Adenoma
Infarction
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Pituitary Apoplexy Following Chlorpromazine Stimulation. / Silverman, Victor E.; Boyd, A. E.; Mccrary, John A.; Kohler, Peter.

In: Archives of Internal Medicine, Vol. 138, No. 11, 1978, p. 1738-1739.

Research output: Contribution to journalArticle

Silverman, Victor E. ; Boyd, A. E. ; Mccrary, John A. ; Kohler, Peter. / Pituitary Apoplexy Following Chlorpromazine Stimulation. In: Archives of Internal Medicine. 1978 ; Vol. 138, No. 11. pp. 1738-1739.
@article{ab310743018d4e34bcec021be90744b0,
title = "Pituitary Apoplexy Following Chlorpromazine Stimulation",
abstract = "Chlorpromazine is frequently administered to patients with hyperprolactinemia to stimulate an increase in the serum levels of prolactin. A patient with a prolactin secreting adenoma is described in whom pituitary apoplexy developed in association with a hypotensive episode following the administration of 25 mg of chlorpromazine. Prolactin levels fell from more than 2,000 ng/ml to 340 ng/ml following infarction of the pituitary tumor. Pituitary apoplexy should be considered as a rare complication of chlorpromazine stimulation in a patient with a pituitary tumor.",
author = "Silverman, {Victor E.} and Boyd, {A. E.} and Mccrary, {John A.} and Peter Kohler",
year = "1978",
doi = "10.1001/archinte.1978.03630360108044",
language = "English (US)",
volume = "138",
pages = "1738--1739",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Pituitary Apoplexy Following Chlorpromazine Stimulation

AU - Silverman, Victor E.

AU - Boyd, A. E.

AU - Mccrary, John A.

AU - Kohler, Peter

PY - 1978

Y1 - 1978

N2 - Chlorpromazine is frequently administered to patients with hyperprolactinemia to stimulate an increase in the serum levels of prolactin. A patient with a prolactin secreting adenoma is described in whom pituitary apoplexy developed in association with a hypotensive episode following the administration of 25 mg of chlorpromazine. Prolactin levels fell from more than 2,000 ng/ml to 340 ng/ml following infarction of the pituitary tumor. Pituitary apoplexy should be considered as a rare complication of chlorpromazine stimulation in a patient with a pituitary tumor.

AB - Chlorpromazine is frequently administered to patients with hyperprolactinemia to stimulate an increase in the serum levels of prolactin. A patient with a prolactin secreting adenoma is described in whom pituitary apoplexy developed in association with a hypotensive episode following the administration of 25 mg of chlorpromazine. Prolactin levels fell from more than 2,000 ng/ml to 340 ng/ml following infarction of the pituitary tumor. Pituitary apoplexy should be considered as a rare complication of chlorpromazine stimulation in a patient with a pituitary tumor.

UR - http://www.scopus.com/inward/record.url?scp=0018203359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018203359&partnerID=8YFLogxK

U2 - 10.1001/archinte.1978.03630360108044

DO - 10.1001/archinte.1978.03630360108044

M3 - Article

C2 - 718334

AN - SCOPUS:0018203359

VL - 138

SP - 1738

EP - 1739

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 11

ER -